FY2026 Earnings Estimate for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Femasys in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.40) per share for the year, down from their previous forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Femasys’ FY2027 earnings at ($0.31) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at $0.12 EPS.

Femasys Price Performance

Shares of FEMY opened at $1.56 on Monday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The company has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.22. Femasys has a fifty-two week low of $0.86 and a fifty-two week high of $1.84. The stock has a market capitalization of $35.72 million, a PE ratio of -1.93 and a beta of -2.85.

Institutional Trading of Femasys

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Femasys during the 4th quarter worth $25,000. Jane Street Group LLC acquired a new stake in shares of Femasys during the fourth quarter worth $30,000. XTX Topco Ltd increased its position in shares of Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares during the period. Citadel Advisors LLC acquired a new stake in Femasys during the 4th quarter worth about $45,000. Finally, Northern Trust Corp increased its holdings in shares of Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after purchasing an additional 37,675 shares during the period. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.